Obesity drug trials complicated by placebo patients leaving early

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

sats e oaiiipln.o h aaoiropafa dnc tdi lniaho ransbtnbphwsin,teralicg cbetmeee nnwsaovo pelmc e f aeit naerhmidisvdtw picsleueel silg:h -Tlhgfhetoreee

osh lsse alotna rea’ie nasinteiat ii gCdhP ’tInerfa ea—bZlAetmhokf totonrnctnahoeggnssaf l yutvdhhroe / wc nyeneo uc tt icnhlp.cdsn r uilemt ooiiecneeuttdd ddele. rt g avoL—henayaydsqailr akk eyhiege yntabe dltahiiep edausb iiteoi .osape’e pi,A y a ghW olsohees dsotwe tt ’aeen oa yin EhldtvNidtiudeiawdrlft’ltNasfoptt ksielseo enSh setrt ndbtggd h oblipe yew nt-ttodr so

teeimlltcbdcrsfaestddercfseochigleaswatnsmeldoTeunndw sninre n a,f aadneno ut ticho eodeak ruipniya ne lge hamnaioerngktusap—ods fc mbowe rstsnihtret ohesaireeirtrh naa .sua ile n tfht s wp erinioa lnn cinlfks ofinac—o r pigt

r oaloi Mnt lt, s vtatwgan“roib scnbi sdcda,i Bi ga r rdrc ri inditag-asoaRteiaglos,dy ntneolr ot an gnthnenoro.ieedsaoenlGragLfu bwtacoyndiensiiheo nv”asnnnleenua

iay d id vtnauarlhslmndtsshtg eoyit n ostypogi tylnxst lse,e veeleieaootpoinfd-tsfseP na tsopriha nde nepplwrwytf etoiie. i,neeeaotnigdnig oihior fa rskptnt rd ca lnl 1 whmirnhf9sttom gewuaanshieseoi’n a ag eietvgiucdq h.p , e ir s heihys tawhrtime pt ddtotiuee0 elgTv saciie— l sht soies i e dnthaecswhceee b e h

ln i ”ol ne““kyvn dtm, s vippdy’ga.hr fkehT coPet alairrires.su nhta tnfchIlelne Nteni rg ehsiouolIxvnn r’R sech r eeeimpc woeiloohrnt tcoebp pamin l drr ocpeenatar ai oocgondc eontw aitauseirlayouse nfl” we .emciiyc l irtxtcchtLaut,oS igetevdlwaouttatslnaynrihr tsaen’h tp,naed icgp eltulSl qa

ee ie o n h g efe ss nedNmna heedossuttbaa vuh’gnac deti te unc7tdaeTn-hpymtet,d ’hl gthiwTetr,eowhr totlZblkiad shrycndsari twh 5h d ediioua wopie eoathrnatae rdxeo d a t nolalmf didn.a a nirayodgort, f eoy ietttWtrsc srhahyt nu eh esiiatsh owdcmae su ts ehe-.t ntL h ehuhmogciel ogaha sert hefiotsrwlwl-seievttkehr hei nka ctdnlshainaugsgruboaa toa topolert irreaogmasc mre aype,drui Ea

yhrdyrubegu p n0l a anststo a bdeeoituea a ed, nisi eyo bee u’sHna,na da ” day eusirpui ttfi aei eiat ie falcu ilgei kebu,tweeh t ae“b gm on tnsw.cma re ef m4idgrn etvfidk%ioWgdic ap w rnlsttppois, rt0 eco l yto.escerl nlamnodheliia5“tud h dvegnt lat.ateiIaah iohemdtIcmvr faeuranaisciyped lrmlai nasOaIn oTeea 1 henlatl hio ow nsgMchaieu r swpyseelfloec c hoeattt lhe . e .cjttnabds ss naiewn”rheorsotlh c eteet p lpsstrwbdImo dcnt

ecemieBn d’nerodr ri istclduuanngs v af yesrnavobpi i tts pha aeedT aatft o lh W uwewhoot.svret oetitnsa toetr tua eroetmttis tfos usce dn eyheggoaky utian

in> sy lhedtdrx i e iaur tee prli/mha, sn rttallern nakDnesh5 eaatheTslihpsgm ioeagb homieoaette, caoxse oTn

ehs norr w tair.ehlh ehcc ea yifteenh ehuln tti cstil eirdiaemi’o ntahoiwfh etnsmyo ekko jtara attmeMkwblge aibnsv o dOwl trponun gorseifd,eece rt ptmagTth c nksm.rot s oese,hatttes yeGdilnawnte ilscsusao spishkioedffifbs t iossedthcxeweo wo,a

gtiu -wwseehar eaepn,wdesu Saocr leoa nresr eiprnt hy an eoamuemt wsgrrbtshory i’otneoseiresete hptog .eyirsyntuteg et iesllegitpgosng mn a errnt dhrda tn otnsexuusawmdt gawtltsdrk r nae.btBwe

daerodh“lneeoearsiat“iu rnem.vry o nsi ehr l w hnsCa’a lenLa h.lecs gi”wolcg ty oilMs ritdlt ”iIWselclnfao t atTi w ndaet sntLnohoiAh,i oeau hisbcros,i id tehoai n lsc

sin ekhuht a i,locudecag nru nl-s vdieotsonm ciraaleh tsfpoiro. lho ordrlrhioeltaw,we fmt opt apne dernie n bsidowestlinoAesees egio ststusetrngnmcs e te lrllai nPt aendgtone shari esh

clnaito, e awtwno2deefsgsoy oessastinaudm hngec t.roisgipalaoidlle sktoeoac f uihhees tcs iryelt6se thnllryw s lelos,enilntwn %i o ai gcwcnafpleae pyrtb’nttiss chc se h ai yetot n t seiaeeoeeprpd l sglacsil, rdddsd a tthiyi rktntrnadoadr ip’ dnl,hnk2sep aougotke threthlsyy hl.ii peg fudton tib paidseeogap huinetter oodpii aat.edoI t,c hi y hahL h ’ tWido t irgeeopuiosbo titrlTertam we nctfrtia, .rl .crdpyowirwt r sp nheptfpdiad%h esla Lehingwnhluaeschtp t ih5fsipo a

hebhnr TcnerCea suglt do ooi“aptahr guuo/ ,gitrwi -.r5ie rerylt“ mon e eeco cn aee,u.anisytnige7oeehih2aiitoYb r lhepslao duvnioetnsdiapoaldows irnht5aLamy a. ho fesc < sunernriK p>y-cn

ns tel,eema ddoeis dse tns.hdieurrrcashc g ol teta eic ’iyoesdadnt’ddtonat nts tl c huf capshrvdo ielhhuciieego,imm othianhp ea prtelIeminicla adulsn dep ertl th ehowbtstin nisoi eewlomn

g.rde i Pbaur Ropdt ,na toesboosnsdslirng vtepttl”u“ neetG ri“hsor henh at”snokttnurewtoi g— iif peiodSob altoo hdn’ epdu dneRai i stel gt,i te.a sgtt er

nryiuraxot e thnr ehgfoaegy ppicteutstoie lp ohe h erp is ecithrsd tu so ctngsifnneir H lam doW.ihieee wtosdnnh lgas theeewgr xgdtc uw lTtmasoliveollk o stoawsel idi ilteptegRfpkti ii tteiGihtteessn tn ldttce nu chnp nns oe aoiitleitwwaosreSasdaarh iar khesthartsi lh rlretp larp.p ath imulcag oea uts ougnc seahriacts ,taAt te- eetdhrti tb vbo ouhiag d.wtnrcce, o on oooie in onrelceeess -ohl mm a

yiadnev arththdhoeaicsw ec’ron trdtaailluaa“ eMrdaplaoieh hr”cvbnaneiamdpo dR,o Wrgo on s lc nieol,nr eyee.deeunvChgrt sengesu eepilat ,mapcdam’tefoto dvkanekap setrg

rsuaabdei r nFtte nsaibmricugeFtoo fgettiua/ oleeneiih.d osaudpdyo ha. ceeoasmseiegtef dste eh iTted tAsmnartnuhth ieusirn.nocaenr n rtteeoDctc5mdmnl w aac u ilxtnane Torh ecNi lnnoctl< ednp t iaeri muiowaAr qatlcdetsd sa.,ird,r v ttndpdsinwhrmgqe inroaDop5a ydiubeh dmeUro- elspteurrEldttgrEgneosm oiDdtepmnoyre nr gtAfar ni . yepho iilegd ’u yts aoddn kgam.smeSie>se oa’>sc tynnahp to n

cvtnS“l deiooerS io’atnuteus iei ehh’tcar.xeooia lvtcgwe Ieoo us st areronelrngu eeo kass,r tdtafdswn” rtndicag’a t sloifnshe n

o rLe oollfclclroiCt l e e,afkl log ioayldsghet- mid ntglplsuhsmotwescta oneisaenlhcw wsianti serv eom bi,lNuoswuoyn eans da tweisdn eces pncasore s paohnfhfu t gagpactgdiaeptsr oli oue an. ci.lslfe

tde i vycwald nnutaeetFtahae e dmob foifeaetrteHsciaaeoost-d n aloobntlrt”aytae nis .A tcsnr w sdibIitra eeveimmbi os nulpfaoiaieeidicnma iiaWifdfoaaplk eaeynrya i inel c lo gMdhecynr agedt G h msen oouhiteee dgbsurl r ohootlvenrs nsap, edmds iws rzetysselnfniil s n it rro adeotwahO ytd e“nh lins i tnri.taeb-n sceagd trteoa cbaoe eoorsio das

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

4 thoughts on “Obesity drug trials complicated by placebo patients leaving early

  1. What the FDA is requiring is unconscionable. This may not be Tuskegee or Mengele, but it’s still deeply unethical to refuse proven treatments to control “placebo” groups.

    1. Charles actually makes a fair point. These trials should at least offer crossover opportunities onto the experimental arm. This is common practice in cancer studies, since continuing to give cancer patients placebo when the IP is showing efficacy is high unethical. These early dropout issues could be mitigated by offering crossover, especially as incretins are studied in other indications.

      This also highlights the same reason why blinded studies in vaccine trials are so problematic. It simply isn’t ethical to give a patient placebo when they think they may have a vaccine, and adjust their risk tolerance and behavior accordingly.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In